Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

NCT07342244 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

AML
AML (Acute Myeloid Leukemia)

Interventions

DRUG: CLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation

Sponsor

Donghua Zhang